Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Hospital Using PerkinElmer Tools for Newborn Screening Program

NEW YORK (GenomeWeb News) — Capital Health of Alberta is using PerkinElmer’s mass spectrometers, reagents, and software in a newborn screening program, PerkinElmer said today.

Under a multi-year agreement, the Edmonton-based Capital Health has bought PerkinElmer’s tandem mass spectrometry systems, reagent kits, and its Specimen Gate software to screen newborns for 17 hereditary metabolic disorders, including cystic fibrosis.  

PerkinElmer said the program will cover the entire province, and makes Alberta the first in Canada to screen all newborns for cystic fibrosis, the company said.  

Financial terms of the agreement were not released.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.